|
1
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263.
2024.PubMed/NCBI
|
|
2
|
Cao W, Qin K, Li F and Chen W:
Socioeconomic inequalities in cancer incidence and mortality: An
analysis of GLOBOCAN 2022. Chin Med J (Engl). 137:1407–1413. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fares J, Fares MY, Khachfe HH, Salhab HA
and Fares Y: Molecular principles of metastasis: A hallmark of
cancer revisited. Signal Transduct Target Ther. 5:282020.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Steens J and Klein D: HOX genes in stem
cells: Maintaining cellular identity and regulation of
differentiation. Front Cell Dev Biol. 10:10029092022. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chin FW, Chan SC and Veerakumarasivam A:
Homeobox gene expression dysregulation as potential diagnostic and
prognostic biomarkers in bladder cancer. Diagnostics (Basel).
13:26412023. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Feng Y, Zhang T, Wang Y, Xie M, Ji X, Luo
X, Huang W and Xia L: Homeobox genes in cancers: From
carcinogenesis to recent therapeutic intervention. Front Oncol.
11:7704282021. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yadav C, Yadav R, Nanda S, Ranga S, Ahuja
P and Tanwar M: Role of HOX genes in cancer progression and their
therapeutical aspects. Gene. 919:1485012024. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jasim SA, Farhan SH, Ahmad I, Hjazi A,
Kumar A, Jawad MA, Pramanik A, Altalbawy FMA, Alsaadi SB and
Abosaoda MK: Role of homeobox genes in cancer: Immune system
interactions, long non-coding RNAs, and tumor progression. Mol Biol
Rep. 51:9642024. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gill HK, Yin S, Nerurkar NL, Lawlor JC,
Lee C, Huycke TR, Mahadevan L and Tabin CJ: Hox gene activity
directs physical forces to differentially shape chick small and
large intestinal epithelia. Dev Cell. 59:2834–2849.e9. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang LT, Chiou SS, Chai CY, His E,
Yokoyama KK, Wang SN, Huang SK and Hsu SH: Intestine-specific
homeobox gene ISX integrates IL6 signaling, tryptophan catabolism,
and immune suppression. Cancer Res. 77:4065–4077. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang LT, Liu KY, Jeng WY, Chiang CM, Chai
CY, Chiou SS, Huang MS, Yokoyama KK, Wang SN, Huang SK and Hsu SH:
PCAF-mediated acetylation of ISX recruits BRD4 to promote
epithelial-mesenchymal transition. EMBO Rep. 21:e487952020.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Devos H, Zoidakis J, Roubelakis MG,
Latosinska A and Vlahou A: Reviewing the regulators of COL1A1. Int
J Mol Sci. 24:100042023. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Selvaraj V, Sekaran S, Dhanasekaran A and
Warrier S: Type 1 collagen: Synthesis, structure and key functions
in bone mineralization. Differentiation. 136:1007572024. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li X, Sun X, Kan C, Chen B, Qu N, Hou N,
Liu Y and Han F: COL1A1: A novel oncogenic gene and therapeutic
target in malignancies. Pathol Res Pract. 236:1540132022.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xiao X, Long F, Yu S, Wu W, Nie D, Ren X,
Li W, Wang X, Yu L, Wang P and Wang G: Col1A1 as a new decoder of
clinical features and immune microenvironment in ovarian cancer.
Front Immunol. 15:14960902025. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu Y, Xue J, Zhong M, Wang Z, Li J and
Zhu Y: Prognostic prediction, immune microenvironment, and drug
resistance value of collagen type I alpha 1 chain: From
gastrointestinal cancers to pan-cancer analysis. Front Mol Biosci.
8:6921202021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang C, Liu S, Wang X and Liu H, Zhou X
and Liu H: COL1A1 Is a potential prognostic biomarker and
correlated with immune infiltration in mesothelioma. Biomed Res
Int. 2021:53209412021. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ribeiro Gomes J and Cruz MRS: Combination
of afatinib with cetuximab in patients with EGFR-mutant
non-small-cell lung cancer resistant to EGFR inhibitors. Onco
Targets Ther. 8:1137–1142. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Della Corte CM, Fasano M, Ciaramella V,
Cimmino F, Cardnell R, Gay CM, Ramkumar K, Diao L, Di Liello R,
Viscardi G, et al: Anti-tumor activity of cetuximab plus avelumab
in non-small cell lung cancer patients involves innate immunity
activation: Findings from the CAVE-Lung trial. J Exp Clin Cancer
Res. 41:1092022. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chanvorachote P, Petsri K and Thongsom S:
Epithelial to mesenchymal transition in lung cancer: Potential
EMT-targeting natural product-derived compounds. Anticancer Res.
42:4237–4246. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ding Y, Zhang M, Hu S, Zhang C, Zhou Y,
Han M, Li J, Li F, Ni H, Fang S and Chen Q: MiRNA-766-3p inhibits
gastric cancer via targeting COL1A1 and regulating PI3K/AKT
signaling pathway. J Cancer. 15:990–998. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang Y, Mei X, Song W, Wang C and Qiu X:
LncRNA LINC00511 promotes COL1A1-mediated proliferation and
metastasis by sponging miR-126-5p/miR-218-5p in lung
adenocarcinoma. BMC Pulm Med. 22:2722022. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li Y, Sun R, Zhao X and Sun B: RUNX2
promotes malignant progression in gastric cancer by regulating
COL1A1. Cancer Biomark. 31:227–238. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang Z, Wang Y, Zhang J, Zhong J and Yang
R: COL1A1 promotes metastasis in colorectal cancer by regulating
the WNT/PCP pathway. Mol Med Rep. 17:5037–5042. 2018.PubMed/NCBI
|
|
26
|
Huang C, Yang X, Han L, Fan Z, Liu B,
Zhang C and Lu T: The prognostic potential of alpha-1 type I
collagen expression in papillary thyroid cancer. Biochem Biophys
Res Commun. 515:125–132. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ma HP, Chang HL, Bamodu OA, Yadav VK,
Huang TY, Wu ATH, Yeh CT, Tsai SH and Lee WH: Collagen 1A1 (COL1A1)
is a reliable biomarker and putative therapeutic target for
hepatocellular carcinogenesis and metastasis. Cancers (Basel).
11:7862019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yang Z, Liu B, Lin T, Zhang Y, Zhang L and
Wang M: Multiomics analysis on DNA methylation and the expression
of both messenger RNA and microRNA in lung adenocarcinoma. J Cell
Physiol. 234:7579–7586. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hou L, Lin T, Wang Y, Liu B and Wang M:
Collagen type 1 alpha 1 chain is a novel predictive biomarker of
poor progression-free survival and chemoresistance in metastatic
lung cancer. J Cancer. 12:5723–5731. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Noorolyai S, Shajari N, Baghbani E,
Sadreddini S and Baradaran B: The relation between PI3K/AKT
signalling pathway and cancer. Gene. 698:120–128. 2019. View Article : Google Scholar : PubMed/NCBI
|
